6.60
-0.59 (-8.15%)
| Previous Close | 7.18 |
| Open | 7.30 |
| Volume | 38,008 |
| Avg. Volume (3M) | 76,946 |
| Market Cap | 98,813,584 |
| Price / Sales | 2.36 |
| Price / Book | 6.05 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2026 |
| TTM Dividend Yield | 22.75% |
| Profit Margin | -7.98% |
| Operating Margin (TTM) | 11.03% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 37.80% |
| Total Debt/Equity (MRQ) | 36.84% |
| Current Ratio (MRQ) | 1.25 |
| Operating Cash Flow (TTM) | 5.42 M |
| Levered Free Cash Flow (TTM) | 3.56 M |
| Return on Assets (TTM) | -2.70% |
| Return on Equity (TTM) | -11.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Cumberland Pharmaceuticals Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -0.3 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | 0.1 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.00 |
Select this tab to load the latest available analysis.
|
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 41.55% |
| % Held by Institutions | 28.76% |
No data within this time range.
No data within this time range.
| TTM Dividend Yield | 22.75% |
| Expected Next Dividend Payment | Jul 2027 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 03 Aug 2026 | 13 Jul 2026 | 31 Jul 2026 | 1.5 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 1.50 | 1 | 22.75 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |